JAMA Oncology highlights disparities in race reporting and diversity in clinical trials in the cancer field.Along with their colleagues, Dr.
Jonathan Loree, a medical oncologist and assistant professor at the University of British Columbia in Vancouver in Canada and Dr.
Kanwal Raghav, an associate professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston analyzed 230 oncology clinical trials.
These trials took place between 2008–2018 and resulted in the Food and Drug Administration (FDA) approving cancer drugs. They found that only 145 (63%) of the 230 trials, included any information about the participant’s race.